www.klinickafarmakologie.cz / Klin Farmakol Farm2021; 35(4): 112–117 / KLINICKÁ FARMAKOLOGIE A FARMACIE 117 HLAVNÍ TÉMA Obtížně léčitelná psoriatická artritida – kazuistika LITERATURA 1. Gottlieb A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J. Am Acad Dermatol, 2008;58:851–864. 2. Migkos MP, Somarakis GP, Marketseli TE et al. Epidemiological characteristics of psoriatic arthritis. Clin Exp Rheumatol 2019;37:324–332. 3. Prey S. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J. Eur. Acad Dermatol Venereol. 2010;24(Suppl. 2):31–35. 4. Qureshi AA. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46–51. 5. Štolfa J. Současný pohled na psoriatickou artritidu, Acta Medicinae, 2012;4:24–29. 6. Štolfa J, Štork J. Psoriatická artritida a psoriaza.1thed. Maxdorf, 2007:22–42. 7. Wittkowski KM. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS ONE. 2011;6:e20279. 8. Wilson FC. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum, 2009;61:233–239. 9. Mc Gonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol. Venereol. 2009;23(Suppl. 1):9–13. 10. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumato, 2001;28:1842–1846. 11. Štolfa J, Vencovský J, Pavelka K. Doporučené léčebné postupy pro psoriatickou artritidu. Česká revmatologie 2016;24:142–152. 12. Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update, Ann Rheum Dis 2020;79:700–712. 13. Štolfa J. Biologická léčba psoriatické artritidy, Vnitřní lékařství, 2018;64(2):127–135. 14. Lie E, van der Heijde D, Uhlig T et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:671–676. 15. Mease PJ, Gladman DD, Collier DH et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 2019;71:1112–1124. 16. Nash P, Kirkham B, Okada M et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo- -controlled period of the SPIRIT-P2 phase 3 trial. The Lancet 2017;389:2317–2327. 17. McInnes IB, Kavanaugh A, Gottlieb AB et al. Ef ficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780–789. 18. Kristensen LE, Lie E, Jacobsson LTH et al. Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden. J Rheumatol 2016;43:81–87. 19. Mease P, Hall S, FitzGerald O et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 2017;377:1537–1550. 20. Gladman D, Rigby W, Azevedo VF et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 2017;377:1525–1536.
RkJQdWJsaXNoZXIy NDA4Mjc=